Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CareRxFRA:29C1 66 5-Year Yield-on-Cost % is 2.42 as of Aug. 09, 2026, which is 130% above its 10-year median of 1.05. GuruFocus rates FRA:29C1 with a GF Score™ of 66/100 and a GF Value™ of €1.37. The stock has 3 warning signs investors should review. Among 275 Healthcare Providers & Services companies, CareRx ranks worse than 55.64% on this metric.
CareRx's yield on cost for the quarter that ended in Jun. 2026 was 2.42.
The historical rank and industry rank for CareRx's 5-Year Yield-on-Cost % or its related term are showing as below:
FRA:29C1'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.51 Med: 1.05 Max: 2.42
Current: 2.42
During the past 13 years, CareRx's highest Yield on Cost was 2.42. The lowest was 0.51. And the median was 1.05.
FRA:29C1's 5-Year Yield-on-Cost % is ranked worse than 55.64% of 275
companies
in the Healthcare Providers & Services industry
Industry Median: 2.9
vs FRA:29C1: 2.42
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
CareRx 5-Year Yield-on-Cost % Related Terms
FRA:29C1 vs HCA, THC, DVA: 5-Year Yield-on-Cost % Comparison
For the Medical Care Facilities subindustry, CareRx's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CareRx 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, CareRx's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where CareRx's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of CareRx is calculated as
CareRx (FRA:29C1) has a 5-Year Yield-on-Cost % of 2.42 as of Aug. 09, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on CareRx and its competitors. This is 130% above median its historical median of 1.05. Over the past decade, CareRx's 5-Year Yield-on-Cost % has ranged from 0.51 to 2.42. According to the industry distribution chart, CareRx ranks #153 out of 275 companies in the Healthcare Providers & Services industry, placing it in the top 55.6%.
Is CareRx's 5-Year Yield-on-Cost % too high?
CareRx's current 5-Year Yield-on-Cost % of 2.42 is 130% above median its 10-year median of 1.05. Over the past 10 years, this metric has ranged from a low of 0.51 to a high of 2.42. The Healthcare Providers & Services industry median 5-Year Yield-on-Cost % is 2.90. CareRx's value of 2.42 is 16.6% below this industry median. Based on the distribution chart, CareRx ranks #153 out of 275 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, CareRx has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does CareRx's 5-Year Yield-on-Cost % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, CareRx ranks #153 out of 275 companies for 5-Year Yield-on-Cost %. This places CareRx in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.90. CareRx's value of 2.42 is 16.6% below this benchmark. Historically, CareRx's own 5-Year Yield-on-Cost % has ranged from 0.51 to 2.42 over the past decade. While the company's 10-year median is 1.05 vs. the industry median of 2.90, CareRx has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.90, based on 275 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CareRx's current 5-Year Yield-on-Cost % of 2.42 is 16.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on CareRx and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CareRx's current 5-Year Yield-on-Cost % is 2.42, which is 130% above median its own 10-year median of 1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CareRx stock overvalued right now?
CareRx (FRA:29C1) has a current 5-Year Yield-on-Cost % of 2.42. The stock's GF Value™ is €1.37, compared to a current price of €2.04 — trading 48.9% above its estimated fair value. The current 5-Year Yield-on-Cost % is 2.42, which is 130% above median its 10-year median of 1.05 and 16.6% below the Healthcare Providers & Services industry median of 2.90. CareRx's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For CareRx (FRA:29C1), the current 5-Year Yield-on-Cost % is 2.42 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CareRx (FRA:29C1) Overvalued in 2026?
Based on GuruFocus' analysis, CareRx stock appears to be overvalued.
The current stock price of €2.04 is trading 48.9% above its estimated GF Value™ of €1.37.
Key valuation signals for FRA:29C1:
5-Year Yield-on-Cost %: 2.42 (130% above median its 10-year median of 1.05)
GF Value™: €1.37 vs. price of €2.04 (48.9% above fair value)
Industry Position: 16.6% below the Healthcare Providers & Services median (#153 of 275)
No single metric tells the full story. See the FRA:29C1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CareRx Corp is a provider of specialty pharmacy services to seniors. The company is a national organization with a large network of pharmacy fulfilment centers strategically located across the country. This allows it to deliver medications in a timely and cost-effective manner and quickly respond to routine changes in medication management. It takes an active role in working with its home operator partners to promote resident health, staff education and medication system quality and efficiency. The Company has one reportable segment which consists of the Company-owned and operated institutional pharmacy business. Geographically it derives revenue from the sales of goods and capitated service fees in Ontario and Western Canada.
66GF Score
Get the complete analysis for FRA:29C1
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:29C1 has been successfully added to your 
